No headlines found.
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Wed, 2-Sep 4:30 PM ET)
Globe Newswire (Wed, 12-Aug 7:30 AM ET)
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
Globe Newswire (Mon, 29-Jun 7:30 AM ET)
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
Xilio Therapeutics trades on the NASDAQ stock market under the symbol XLO.
As of September 23, 2026, XLO stock price declined to $8.94 with 1,221 million shares trading.
XLO has a beta of 0.10, meaning it tends to be less sensitive to market movements. XLO has a correlation of 0.00 to the broad based SPY ETF.
XLO has a market cap of $58.78 million. This is considered a Micro Cap stock.
Last quarter Xilio Therapeutics reported $19 million in Revenue and -$.33 earnings per share. This beat revenue expectation by $6 million and exceeded earnings estimates by $.26.
In the last 3 years, XLO traded as high as $40.51 and as low as $6.47.
The top ETF exchange traded funds that XLO belongs to (by Net Assets): VTI, VXF, DCOR, DFAC.
XLO has underperformed the market in the last year with a price return of -17.3% while the SPY ETF gained +16.9%. XLO has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +0.4% and -0.3%, respectively, while the SPY returned +4.9% and +1.0%, respectively.
XLO support price is $8.66 and resistance is $9.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XLO shares will trade within this expected range on the day.